[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632066":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":21,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":21,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":21,"enrollmentInfo":61,"targetDuration":21,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":34,"whyStopped":21,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Eligible participants","EXPERIMENTAL","Sequential \\[18F\\]-FDG PET\u002FCT and \\[68Ga\\]Ga-PFD3 PET\u002FCT",[13,14],"Diagnostic Test: Sequential [18F]-FDG PET\u002FCT","Diagnostic Test: [68Ga]Ga-PFD3 PET\u002FCT scan",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DIAGNOSTIC_TEST","Sequential [18F]-FDG PET\u002FCT","Based on individual clinical circumstances, eligible patients will undergo sequential \\[18F\\]FDG PET\u002FCT and \\[68Ga\\]Ga-PFD3 PET\u002FCT scans within one week.",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"[68Ga]Ga-PFD3 PET\u002FCT scan",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":21,"email":30},"Tingting Yuan, M. D.","CONTACT","+86-13051707479","biluohtt@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Peking university first hospital nuclear medicine","RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":27,"role":28,"phone":29,"phoneExt":21,"email":30},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Tingting Yuan","Attending physician","100632066","phase-1-68ga-pfd3-pet-imaging-for-the-diagnosis-and-evaluation-of-small-cell-lung-cancer-100632066",false,"NCT07508852","68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer","Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET\u002FCT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Adults.\n* Histologically confirmed small cell lung cancer (SCLC).\n* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.\n* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Breastfeeding.\n* Acute psychiatric disorders.\n* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).\n* Inability to complete the study procedures as anticipated.\n* Prior therapy targeting DLL3.","ALL","18 Years",{"count":62,"type":63},30,"ESTIMATED","INTERVENTIONAL",[66,67],"PHASE1","PHASE2","This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).",[70,71,72,73,74],"SCLC","SCLC, Extensive Stage","SCLC, Limited Stage","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )",[70,76,77,78,79,80,81,82,83],"small cell lung cancer","PET\u002FCT","PET","DLL3","Delta-like ligand 3","imaging","diagnosis","evaluation","2026-06-16",{"date":86,"type":87},"2026-06-18","ACTUAL",{"date":89,"type":87},"2025-10-22",{"date":91,"type":63},"2027-12-31",{"name":5,"class":6},1]